Monday, May 29, 2023 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

BOSTON - Directors inflated the price of Ariad Pharmaceuticals stock by failing to disclose side effects of its cancer drug Iclusig (ponatinib), and the share price dropped by 66 percent when the truth came out, shareholders claim in Federal Court.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.